Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07584109
Starting soon Not applicable

The Effect of Value Clarification Based on Meleis's Transition Theory on Menopausal Symptoms, Depression, Anxiety, Stress, and Quality of Life in Perimenopausal Women

NCT07584109 · tracked via the Priya Life Science Turkey tracker
Sponsor
Ordu University
Phase
Not applicable
Started
2026-05-04
Last updated
2026-05-13

Condition(s) studied

Menopausal Women

Investigational drug(s) / intervention(s)

value clarificationcontrol group

value clarification: The intervention group will be given written clarification of values. After the pre-test, clarification will be applied once a month for 3 months, and the scales will be completed in the 3rd and 6th months.

control group: The scales will be administered to the control group in parallel on the same dates.

Study summary

Menopause is a life stage influenced not only by hormonal factors but also by psychological, social, and cultural factors. Symptoms such as hot flashes, sleep problems, and mood changes may occur, and their severity depends on how a woman perceives and copes with this period.

The study aims to examine the effects of the "Value Clarification" method based on Meleis Transition Theory on menopausal symptoms, depression, anxiety, stress, and quality of life in women during menopause.

Eligibility

Sex
FEMALE
Min age
45 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Women who agree to participate in the study, * Have at least a primary school education, * Understand, read, and write Turkish, * Have no communication barriers, * Are between 45-55 years of age, * Have started experiencing menstrual cycle irregularities or have not menstruated, * Have experienced at least one menopausal symptom in the last 6 months (hot flashes, irritability, sleep problems, urogenital complaints, etc.), * Are in the perimenopausal period according to the Straw Classification of Reproductive Aging in Women criteria, * Women who have entered menopause naturally will be included in the study. Exclusion Criteria: * Women who: * Use any complementary or alternative treatment methods (such as Reiki, phytoestrogens, acupressure), * Use hypnotic or sedative medications, * Have a diagnosed psychiatric illness, * Have a gynecological problem causing menstrual irregularities, * Have entered menopause as a result of any surgical operation such as a hysterectomy, * Are receiving hormone replacement therapy will be excluded from the study.

Primary outcome measure(s)

  • Change in menopausal symptoms measured by the Menopausal Symptom Assessment Scale — 0-6 month
    The value explanation method based on transition theory improves menopausal symptoms in women when applied to perimenopausal women. The Menopausal Symptom Assessment Scale was developed to measure the severity of menopausal symptoms. The scale, adapted into Turkish, consists of 11 items and 3 sub-dimensions. These sub-dimensions are somatic complaints (items 1, 2, 3, and 11), psychological complaints (items 4, 5, 6, and 7), and urogenital complaints (items 8, 9, and 10). The Likert-type scale, which includes menopausal complaints, uses the options: 0: None, 1: Mild, 2: Moderate, 3: Severe, and 4: Very severe. The total score is calculated from the scores obtained from each item. The lowest possible score is "0," and the highest is "44." An increase in the total score indicates an increase in the severity of complaints and a negative impact on quality of life.

Trial sites (1)

FacilityCityRegionStatus
Corum Private Hospital Çorum Centre

More Ordu University trials in Turkey

Turkish Version of Back Pain Knowledge and Beliefs Survey Active, not recruiting
Hypoglycemia Fear Affect Autonomic Function, Physical Activity, and Exercise Capacity in Type I Diabetes Starting soon
Fascial Plane Blocks and Quality of Recovery in Cardiac Surgery Recruiting
The Effect of Self-Compassion Based Birth Preparation Program Enrolling by invitation
Turkish Translation of SportsConcussion Assesment Tool 6 Active, not recruiting

Other trials for the same condition

Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy Starting soon
The Effect of Animation-Based Education on Menopausal Women's Attitudes, Behaviors, and Screening Test Participation Regarding Breast Cancer Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07584109 on ClinicalTrials.gov ↗ ← All trials in Turkey